FR2850970B1 - Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique - Google Patents

Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Info

Publication number
FR2850970B1
FR2850970B1 FR0301478A FR0301478A FR2850970B1 FR 2850970 B1 FR2850970 B1 FR 2850970B1 FR 0301478 A FR0301478 A FR 0301478A FR 0301478 A FR0301478 A FR 0301478A FR 2850970 B1 FR2850970 B1 FR 2850970B1
Authority
FR
France
Prior art keywords
specific
application
anticancer agent
chemical derivatives
dna structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0301478A
Other languages
English (en)
French (fr)
Other versions
FR2850970A1 (fr
Inventor
Augustin Hittinger
Thomas Caulfield
Patrick Maillet
Herve Bouchard
Eliane Mandine
Chafke Belmokhtar
Jean Louis Mergny
Lionel Guittat
Jean Francois Riou
Dennis Gomez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Aventis Pharma SA
Institute Curie
National Museum of Natural History
Université de Reims Champagne-Ardenne
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Centre National de la Recherche Scientifique
Commissariat a lEnergie Atomique CEA
Aventis Pharma SA
Institute Curie
National Museum of Natural History
Université de Reims Champagne-Ardenne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0301478A priority Critical patent/FR2850970B1/fr
Application filed by Centre National de la Recherche Scientifique, Commissariat a lEnergie Atomique CEA, Aventis Pharma SA, Institute Curie, National Museum of Natural History, Université de Reims Champagne-Ardenne filed Critical Centre National de la Recherche Scientifique
Priority to PCT/FR2004/000260 priority patent/WO2004072027A2/fr
Priority to AU2004210753A priority patent/AU2004210753A1/en
Priority to BRPI0407320-7A priority patent/BRPI0407320A/pt
Priority to CA002514105A priority patent/CA2514105A1/fr
Priority to JP2006502131A priority patent/JP2006518726A/ja
Priority to EP04708378A priority patent/EP1603898A2/fr
Priority to MXPA05007648A priority patent/MXPA05007648A/es
Priority to US10/773,806 priority patent/US20070232572A1/en
Publication of FR2850970A1 publication Critical patent/FR2850970A1/fr
Application granted granted Critical
Publication of FR2850970B1 publication Critical patent/FR2850970B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0301478A 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique Expired - Fee Related FR2850970B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
AU2004210753A AU2004210753A1 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent
BRPI0407320-7A BRPI0407320A (pt) 2003-02-07 2004-02-05 derivados quìmicos que se ligam de maneira muito especìfica às estruturas de dna em g-quadrúples e sua aplicação como agente anticanceroso especìfico
CA002514105A CA2514105A1 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
PCT/FR2004/000260 WO2004072027A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
JP2006502131A JP2006518726A (ja) 2003-02-07 2004-02-05 G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用
EP04708378A EP1603898A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d adn en g-quadruplexe et leur application comme agent anticancereux specifique
MXPA05007648A MXPA05007648A (es) 2003-02-07 2004-02-05 Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.
US10/773,806 US20070232572A1 (en) 2003-02-07 2004-02-06 Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Publications (2)

Publication Number Publication Date
FR2850970A1 FR2850970A1 (fr) 2004-08-13
FR2850970B1 true FR2850970B1 (fr) 2006-07-07

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0301478A Expired - Fee Related FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Country Status (8)

Country Link
EP (1) EP1603898A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518726A (cg-RX-API-DMAC7.html)
AU (1) AU2004210753A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407320A (cg-RX-API-DMAC7.html)
CA (1) CA2514105A1 (cg-RX-API-DMAC7.html)
FR (1) FR2850970B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05007648A (cg-RX-API-DMAC7.html)
WO (1) WO2004072027A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
EP2061464A2 (en) * 2006-09-14 2009-05-27 Ramot, at Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
JP4410844B1 (ja) 2008-05-27 2010-02-03 パナソニック株式会社 G−quadruplex検出方法、G−quadruplex形成DNA検出方法およびテロメラーゼ活性測定方法
JP4510929B1 (ja) 2009-04-09 2010-07-28 パナソニック株式会社 テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤
CN108066340B (zh) * 2016-11-10 2020-10-27 中国科学院化学研究所 药物组合物
CN108066341B (zh) * 2016-11-10 2020-10-30 中国科学院化学研究所 化合物在制备抗癌药物中的用途
WO2018211148A1 (en) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Bisquinolium derivatives for preventing or treating ebv-related cancers
CN113272294A (zh) * 2018-08-24 2021-08-17 雅典学院生物医学研究基金会 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149402A0 (en) * 1999-11-29 2002-11-10 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
FR2819255B1 (fr) * 2001-01-09 2003-02-28 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent

Also Published As

Publication number Publication date
BRPI0407320A (pt) 2006-02-21
EP1603898A2 (fr) 2005-12-14
MXPA05007648A (es) 2006-12-15
WO2004072027A3 (fr) 2004-09-23
WO2004072027A2 (fr) 2004-08-26
JP2006518726A (ja) 2006-08-17
AU2004210753A1 (en) 2004-08-26
CA2514105A1 (fr) 2004-08-26
FR2850970A1 (fr) 2004-08-13

Similar Documents

Publication Publication Date Title
AP2328A (en) Synthetic compounds useful as nodulation agents ofleguminous plants and preparation processes thereof.
EP1633335A4 (en) IMPROVED ABSORPTION OF FAT-SOLUBLE NUTRIENTS
EP1880206A4 (en) MULTIPLEX INPUT OF NUCLEIC ACIDS
DE602004004957D1 (de) Härtbare wässrige Zusammensetzung und ihre Verwendung als Vliesstoff-Bindemittel
WO2004089947A3 (de) Neue verbindungen mit antibakterieller aktivität
IL175185A0 (en) Multiplexed nucleic acid analysis by fragmentation of double-stranded dna
EP2162555A4 (en) SPECIFIC AMPLIFICATION OF TUMOR-SPECIFIC DNA SEQUENCES
EP1781800A4 (en) PROCESS FOR PLASMID DNA FERMENTATION
EP1633871A4 (en) DOUBLE-STRUCTURED NUCLEIC ACID
TWI347184B (en) Methods of treating hiv infection
EP2046361A4 (en) OSTEOUS AMPLIFIER COMPOSITION
EP1831238A4 (en) Fluorous oligonucleotide reagents and affinity purification of oligonucleotides
ITTO20040745A1 (it) Struttura di filtro dell'aria
EP1756129A4 (en) NEW INTERCALATORS INTO THE DNA
DE60211579D1 (de) Filter und dessen Herstellungverfahren
EP2080126A4 (en) Filtering of data items
EP1705247A4 (en) DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND
GB0315494D0 (en) Compounds which bind to the active site of protein kinase enzymes
FR2884244B1 (fr) Obtention de cristaux de dinitroamidure d'ammonium (adn); cristaux d'adn et les composites energetiques en contenant.
PT1603550E (pt) Composição farmacêutica que compreende ácido 5-metil-2-2¿- (cloro-6¿-fluoroanilino)fenilacético
EP1978956A4 (en) COMPLEX FORMULATION WITH AMLODIPINCAMSYLATE AND SIMVASTATIN AND METHOD OF MANUFACTURING THEREOF
EP1633412A4 (en) FORMATION OF A POLYMERIC BODY
IL174325A (en) HIV immunogenic DNA composition
EP1730286A4 (en) THERAPEUTIC ANTICIPLE DNA
EP1652915A4 (en) PROCESS FOR REMOVING DSRNA AND FOR SYNTHESIS OF RNA

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101029